Anthony Mancini Sells 3,708 Revolution Medicines Shares at $200.54 Each ($743,285 Total)

On September 29, 2026, Anthony Mancini sold 3,708 Revolution Medicines, Inc. (ticker RVMD) shares at $200.54 per share, generating a total value of $743,285 as reported in the SEC-form filed Form 4.

Who is Anthony Mancini and What is His Real Role at Revolution Medicines?

Anthony Mancini appears in the Form 4 filing as an insider of Revolution Medicines, Inc. The "Role" field refers to the remarks section of the form, where companies typically specify the exact title of the officer or board member involved. This reference indicates that Mancini holds a position that grants him access to material information, in compliance with U.S. securities regulations.

In publicly traded companies, individuals designated as insiders include executives (CEO, CFO, COO), board members, and key committee members (audit, compensation). Their positions give them the ability to receive or influence strategic, financial, or operational decisions before they become public. This insight into research projects, clinical trials, or licensing agreements can significantly impact stock prices.

The fact that Mancini's role is mentioned in the remarks section confirms that he is subject to the transparency obligations imposed by the Securities and Exchange Commission (SEC). Any transaction executed by such an insider must be reported within two business days of the trade to ensure market fairness and prevent misuse of confidential information.

Transaction Details: 3,708 Shares at $200.54 USD Each

The filing indicates that the exact number of shares sold is 3,708, with each share sold at $200.54 USD. The transaction was executed on September 29, 2026, the date listed on the form, which triggers the two-day reporting requirement. The total sale amount, calculated by multiplying the number of shares by the per-share price, amounts to $743,285, representing the gross value of the transaction.

Why Insiders Sell Their Shares – Possible Reasons

The motives behind an insider selling shares are varied and should not be interpreted as a verdict on the health of the company. Portfolio diversification is a common reason; an executive might reduce their exposure to one company to balance overall risk. Tax planning also plays a role; selling shares before the end of the fiscal year can allow for tax-loss harvesting or gain recognition, depending on individual strategy.

Personal liquidity needs, such as purchasing real estate or funding education, may justify a one-time sale. Additionally, insiders may take advantage of elevated stock prices to monetize part of their holdings, particularly when they believe the current price reflects favorable valuation. None of these factors necessarily imply an expectation of a price decline, even though the market often interprets insider sales as bearish signals.

How Individual Investors Track Form 4 Filings

Individual investors can access Form 4 filings through the SEC's free online EDGAR system. Third-party platforms aggregate this data and offer alerts when an insider executes a transaction, enabling real-time monitoring of executives' and board members' stock movements.

It’s important to note that Form 4 filings contain limited information about the transaction itself; they do not specify underlying reasons or the company's overall strategy. Therefore, investors should combine Form 4 analysis with other sources, such as quarterly reports, press releases, and industry analyses, to form a more comprehensive view of the context.